Tailored immunotherapy for HPV positive head and neck squamous cell cancer.
Identifieur interne : 001016 ( Main/Exploration ); précédent : 001015; suivant : 001017Tailored immunotherapy for HPV positive head and neck squamous cell cancer.
Auteurs : Neil Gildener-Leapman [États-Unis] ; John Lee [États-Unis] ; Robert L. Ferris [États-Unis]Source :
- Oral oncology [ 1879-0593 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- isolement et purification : Alphapapillomavirus.
- usage thérapeutique : Anticorps monoclonaux, Vaccins anticancéreux.
- virologie : Carcinome épidermoïde, Tumeurs de la tête et du cou.
- Carcinome épidermoïde, Humains, Immunothérapie, Tumeurs de la tête et du cou.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Cancer Vaccines.
- isolation & purification : Alphapapillomavirus.
- therapy : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- virology : Carcinoma, Squamous Cell, Head and Neck Neoplasms.
- Humans, Immunotherapy.
Abstract
Human papilloma virus (HPV) associated oropharynx carcinoma (OPC) is increasingly common, with a distinct biology from HPV negative OPC. In spite of this better prognosis, morbidity is significant and treatment related after effects can be debilitating. Because the foreign viral proteins that drive HPV+ cancers are known, there are multiple options for tailored immune therapies. Herein we review the immunologic basis for disease and emerging immune therapies. The oncogenesis of HPV+ SCCHN goes beyond cell cycle deregulation, and relies on the immune escape through (E5, E6, and E7) downregulating antigen processing, interferon response, as well as STAT-1 signaling. Individual susceptibilities to HPV infection may vary. The treatment of HPV+ cancers has had a wide range of successes and failures. Perhaps the shining example of immunoprevention has been the L1 protein vaccines developed for cervical cancer prevention, however this vaccine has not been beneficial for people already infected. Therefore multiple strategies have been employed in the cancer therapeutic realm for people with existing disease. These agents range from peptides, to viral vectors, to adoptive cell therapy. In this review we consider the work done in both SCCHN and cervical cancer, as these therapeutic targets are the similar. The listed studies are not exhaustive, but rather illustrate experimental design and approach.
DOI: 10.1016/j.oraloncology.2013.09.010
PubMed: 24126224
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001F06
- to stream PubMed, to step Curation: 001E97
- to stream PubMed, to step Checkpoint: 001E97
- to stream Ncbi, to step Merge: 000403
- to stream Ncbi, to step Curation: 000403
- to stream Ncbi, to step Checkpoint: 000403
- to stream Main, to step Merge: 001036
- to stream Main, to step Curation: 001016
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tailored immunotherapy for HPV positive head and neck squamous cell cancer.</title><author><name sortKey="Gildener Leapman, Neil" sort="Gildener Leapman, Neil" uniqKey="Gildener Leapman N" first="Neil" last="Gildener-Leapman">Neil Gildener-Leapman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Otolaryngology Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States. Electronic address: gildenerleapmannr@upmc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Otolaryngology Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Lee, John" sort="Lee, John" uniqKey="Lee J" first="John" last="Lee">John Lee</name><affiliation wicri:level="2"><nlm:affiliation>Sanford Ear, Nose, and Throat Clinic, Sioux Falls, SD, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sanford Ear, Nose, and Throat Clinic, Sioux Falls, SD</wicri:regionArea><placeName><region type="state">Dakota du Sud</region></placeName></affiliation></author><author><name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L" last="Ferris">Robert L. Ferris</name><affiliation wicri:level="2"><nlm:affiliation>Department of Otolaryngology Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Otolaryngology Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24126224</idno><idno type="pmid">24126224</idno><idno type="doi">10.1016/j.oraloncology.2013.09.010</idno><idno type="wicri:Area/PubMed/Corpus">001F06</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F06</idno><idno type="wicri:Area/PubMed/Curation">001E97</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E97</idno><idno type="wicri:Area/PubMed/Checkpoint">001E97</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001E97</idno><idno type="wicri:Area/Ncbi/Merge">000403</idno><idno type="wicri:Area/Ncbi/Curation">000403</idno><idno type="wicri:Area/Ncbi/Checkpoint">000403</idno><idno type="wicri:Area/Main/Merge">001036</idno><idno type="wicri:Area/Main/Curation">001016</idno><idno type="wicri:Area/Main/Exploration">001016</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tailored immunotherapy for HPV positive head and neck squamous cell cancer.</title><author><name sortKey="Gildener Leapman, Neil" sort="Gildener Leapman, Neil" uniqKey="Gildener Leapman N" first="Neil" last="Gildener-Leapman">Neil Gildener-Leapman</name><affiliation wicri:level="2"><nlm:affiliation>Department of Otolaryngology Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States. Electronic address: gildenerleapmannr@upmc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Otolaryngology Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Lee, John" sort="Lee, John" uniqKey="Lee J" first="John" last="Lee">John Lee</name><affiliation wicri:level="2"><nlm:affiliation>Sanford Ear, Nose, and Throat Clinic, Sioux Falls, SD, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sanford Ear, Nose, and Throat Clinic, Sioux Falls, SD</wicri:regionArea><placeName><region type="state">Dakota du Sud</region></placeName></affiliation></author><author><name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L" last="Ferris">Robert L. Ferris</name><affiliation wicri:level="2"><nlm:affiliation>Department of Otolaryngology Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Otolaryngology Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author></analytic><series><title level="j">Oral oncology</title><idno type="eISSN">1879-0593</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alphapapillomavirus (isolation & purification)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Cancer Vaccines (therapeutic use)</term><term>Carcinoma, Squamous Cell (therapy)</term><term>Carcinoma, Squamous Cell (virology)</term><term>Head and Neck Neoplasms (therapy)</term><term>Head and Neck Neoplasms (virology)</term><term>Humans</term><term>Immunotherapy</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Alphapapillomavirus (isolement et purification)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Carcinome épidermoïde ()</term><term>Carcinome épidermoïde (virologie)</term><term>Humains</term><term>Immunothérapie</term><term>Tumeurs de la tête et du cou ()</term><term>Tumeurs de la tête et du cou (virologie)</term><term>Vaccins anticancéreux (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Cancer Vaccines</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Alphapapillomavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Alphapapillomavirus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Head and Neck Neoplasms</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Vaccins anticancéreux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Tumeurs de la tête et du cou</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Carcinoma, Squamous Cell</term><term>Head and Neck Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Immunotherapy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Carcinome épidermoïde</term><term>Humains</term><term>Immunothérapie</term><term>Tumeurs de la tête et du cou</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Human papilloma virus (HPV) associated oropharynx carcinoma (OPC) is increasingly common, with a distinct biology from HPV negative OPC. In spite of this better prognosis, morbidity is significant and treatment related after effects can be debilitating. Because the foreign viral proteins that drive HPV+ cancers are known, there are multiple options for tailored immune therapies. Herein we review the immunologic basis for disease and emerging immune therapies. The oncogenesis of HPV+ SCCHN goes beyond cell cycle deregulation, and relies on the immune escape through (E5, E6, and E7) downregulating antigen processing, interferon response, as well as STAT-1 signaling. Individual susceptibilities to HPV infection may vary. The treatment of HPV+ cancers has had a wide range of successes and failures. Perhaps the shining example of immunoprevention has been the L1 protein vaccines developed for cervical cancer prevention, however this vaccine has not been beneficial for people already infected. Therefore multiple strategies have been employed in the cancer therapeutic realm for people with existing disease. These agents range from peptides, to viral vectors, to adoptive cell therapy. In this review we consider the work done in both SCCHN and cervical cancer, as these therapeutic targets are the similar. The listed studies are not exhaustive, but rather illustrate experimental design and approach.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Dakota du Sud</li><li>Pennsylvanie</li></region></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Gildener Leapman, Neil" sort="Gildener Leapman, Neil" uniqKey="Gildener Leapman N" first="Neil" last="Gildener-Leapman">Neil Gildener-Leapman</name></region><name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L" last="Ferris">Robert L. Ferris</name><name sortKey="Lee, John" sort="Lee, John" uniqKey="Lee J" first="John" last="Lee">John Lee</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001016 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001016 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24126224
|texte= Tailored immunotherapy for HPV positive head and neck squamous cell cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24126224" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |